Cargando…

A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma

The prognostic role of serum LDH, CA19-9, CRP and ALB in PDAC patients are controversial. In contrast to single factor, there is much less information about the prognostic value of the combination of the four factors in locally advanced and metastatic PDAC patients. It's essential to set up a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yi, Xiao, Xiuying, Wang, Tianyi, Li, Lin, Zhu, Yue, Xu, Haiyan, Chu, Yuening, Jiao, Feng, Cui, Jiujie, Wang, Liwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907678/
https://www.ncbi.nlm.nih.gov/pubmed/29675111
http://dx.doi.org/10.7150/jca.23984
_version_ 1783315582825791488
author Wang, Yi
Xiao, Xiuying
Wang, Tianyi
Li, Lin
Zhu, Yue
Xu, Haiyan
Chu, Yuening
Jiao, Feng
Cui, Jiujie
Wang, Liwei
author_facet Wang, Yi
Xiao, Xiuying
Wang, Tianyi
Li, Lin
Zhu, Yue
Xu, Haiyan
Chu, Yuening
Jiao, Feng
Cui, Jiujie
Wang, Liwei
author_sort Wang, Yi
collection PubMed
description The prognostic role of serum LDH, CA19-9, CRP and ALB in PDAC patients are controversial. In contrast to single factor, there is much less information about the prognostic value of the combination of the four factors in locally advanced and metastatic PDAC patients. It's essential to set up a survival model with the combination of tumor metabolism, tumor biomarker, systemic inflammation and nutritional status to eliminate the prognostic inaccuracy in single biomarker. 94 advanced PDAC patients who received palliative chemotherapy from 2009 to 2017 were recruited for this study. The predictive value of pretreatment serum LDH, CA19-9, CRP and ALB levels for OS were evaluated, and the same as combination of the four factors. It was confirmed that serum LDH, CA19-9, CRP and ALB levels were independent prognostic factors for OS by multivariate analyses. The results of Kaplan-Meier analyses revealed that serum LDH, CA19-9, CRP, ALB levels as well as the combination of the four factors were correlated with OS. It's concluded that the combination of the pretreatment serum LDH, CA19-9, CRP and ALB levels is a prognostic factor for advanced PDAC patients.
format Online
Article
Text
id pubmed-5907678
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-59076782018-04-19 A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma Wang, Yi Xiao, Xiuying Wang, Tianyi Li, Lin Zhu, Yue Xu, Haiyan Chu, Yuening Jiao, Feng Cui, Jiujie Wang, Liwei J Cancer Research Paper The prognostic role of serum LDH, CA19-9, CRP and ALB in PDAC patients are controversial. In contrast to single factor, there is much less information about the prognostic value of the combination of the four factors in locally advanced and metastatic PDAC patients. It's essential to set up a survival model with the combination of tumor metabolism, tumor biomarker, systemic inflammation and nutritional status to eliminate the prognostic inaccuracy in single biomarker. 94 advanced PDAC patients who received palliative chemotherapy from 2009 to 2017 were recruited for this study. The predictive value of pretreatment serum LDH, CA19-9, CRP and ALB levels for OS were evaluated, and the same as combination of the four factors. It was confirmed that serum LDH, CA19-9, CRP and ALB levels were independent prognostic factors for OS by multivariate analyses. The results of Kaplan-Meier analyses revealed that serum LDH, CA19-9, CRP, ALB levels as well as the combination of the four factors were correlated with OS. It's concluded that the combination of the pretreatment serum LDH, CA19-9, CRP and ALB levels is a prognostic factor for advanced PDAC patients. Ivyspring International Publisher 2018-03-22 /pmc/articles/PMC5907678/ /pubmed/29675111 http://dx.doi.org/10.7150/jca.23984 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Wang, Yi
Xiao, Xiuying
Wang, Tianyi
Li, Lin
Zhu, Yue
Xu, Haiyan
Chu, Yuening
Jiao, Feng
Cui, Jiujie
Wang, Liwei
A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
title A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
title_full A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
title_fullStr A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
title_full_unstemmed A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
title_short A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
title_sort survival model in locally advanced and metastatic pancreatic ductal adenocarcinoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907678/
https://www.ncbi.nlm.nih.gov/pubmed/29675111
http://dx.doi.org/10.7150/jca.23984
work_keys_str_mv AT wangyi asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT xiaoxiuying asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT wangtianyi asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT lilin asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT zhuyue asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT xuhaiyan asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT chuyuening asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT jiaofeng asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT cuijiujie asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT wangliwei asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT wangyi survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT xiaoxiuying survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT wangtianyi survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT lilin survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT zhuyue survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT xuhaiyan survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT chuyuening survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT jiaofeng survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT cuijiujie survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma
AT wangliwei survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma